Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 51 No. 4
PSYCHOPHARMACOLOGY BULLETIN

VOL 51 No. 4

Articles in This Issue

ORIGINAL RESEARCH

Obesogenic Medications and Weight Gain Over 24 Weeks in Patients with Depression: Results from the GUIDED Study

Jess G Fiedorowicz, Lisa Brown, James Li, Sagar V Parikh, Boadie W Dunlop, Brent P Forester, Richard C Shelton, Michael E Thase, Matthew Macaluso, Kunbo Yu, John F Greden
Weight gain is a common side-effect of medications used to treat major depressive disorder (MDD). We sought to estimate the frequency of weight gain for obesogenic medications prescribed for MDD and to evaluate if bupropion...
Pages 8-30 Read Article
ORIGINAL RESEARCH

Selective Serotonin Reuptake Inhibitors and Nutraceutical Combination in Major Depression Disorder: A Case-Control Study

Marta Ielmini, Ivano Caselli, Francesca Ceccon, Marcello Diurni, Nicola Poloni, Camilla Callegari
Introduction: Major depressive disorder (MDD) is a primary cause of disability in adults, affecting daily functioning and decreasing quality of life. The focus on the role of nutraceuticals as adjunctive treatments to improve antidepressant response...
Pages 31-39 Read Article
ORIGINAL RESEARCH

Characteristics of Inpatients Prescribed Dopamine Receptor Blocking Agents

Shaina Schwartz, Lauren Dinkla, Jocelyn Pullen, Rachel Bernard, Archana Kumar
Dopamine receptor blocking agents (DRBAs, also known as antipsychotics) are frequently used in hospitalized patients. These medications carry a significant side effect burden and should be used judiciously. This purpose of this study is to...
Pages 51-64 Read Article
DRUG DISPOSITION & PHARMACOKINETICS

Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder

MS Zastrozhin, AV Efimova, VYu Skryabin, VV Smirnov, AE Petukhov, EP Pankratenko, SA Pozdniakov, EV Kaverina, DA Klepikov, EA Grishina, KA Ryzhikova, IV Bure, EA Bryun, DA Sychev
Introduction: Phenazepam is commonly administered to patients diagnosed with major depressive disorder. Some proportion of such patients do not show adequate response to treatment regimen containing phenazepam, whereas many of them experience type A adverse...
Pages 87-104 Read Article
COMPLICATED CASE HISTORY

Clozapine Induced Hypertension and its Association with Autonomic Dysfunction

MB Deepak, Kalra Deeksha, Rajhans Pallavi, Choudhary Hemant, Bajaj Nidhisha, Deep Raman
Clozapine is a second generation antipsychotic agent which is drug of choice for treatment resistant schizophrenia. Tachycardia and postural hypotension are most frequently observed cardiovascular adverse effects, but reports on new-onset persistently elevated blood pressure...
Pages 122-127 Read Article